• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Metastatic Hormone Refractory Prostate Cancer - Pipeline Review, H1 2012 Product Image

Metastatic Hormone Refractory Prostate Cancer - Pipeline Review, H1 2012

  • Published: May 2012
  • 56 pages
  • Global Markets Direct

Metastatic Hormone Refractory Prostate Cancer – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Metastatic Hormone Refractory Prostate Cancer - Pipeline Review, H1 2012', provides an overview of the Metastatic Hormone Refractory Prostate Cancer therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Hormone Refractory Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory Prostate Cancer. 'Metastatic Hormone Refractory Prostate Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metastatic Hormone Refractory Prostate Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Metastatic Hormone Refractory Prostate Cancer
Metastatic Hormone Refractory Prostate Cancer Therapeutics under Development by Companies
Metastatic Hormone Refractory Prostate Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Metastatic Hormone Refractory Prostate Cancer Therapeutics – Products under Development by Companies
Metastatic Hormone Refractory Prostate Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Metastatic Hormone Refractory Prostate Cancer Therapeutics Development
Genentech, Inc.
Oxford BioMedica plc
Millennium Pharmaceuticals, Inc.
Metastatic Hormone Refractory Prostate Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
TAK-700 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD2171 + Docetaxel + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Taxol + Estramustine + Thalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
177Lu Radiolabeled Monoclonal Antibody HuJ591 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZD4054 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZD4054 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TroVax + Docetaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CreaVax-PC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Prednisone + 177Lu-J591 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mitoxantrone + Prednisone + Clodronate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BAY43-9006 + Taxotere - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mitoxantrone + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAK-700 + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DSTP3086S - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RG7450 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metastatic Hormone Refractory Prostate Cancer Therapeutics – Drug Profile Updates
Metastatic Hormone Refractory Prostate Cancer Therapeutics – Discontinued Products
Metastatic Hormone Refractory Prostate Cancer Therapeutics - Dormant Products
Metastatic Hormone Refractory Prostate Cancer – Product Development Milestones
Featured News & Press Releases
Feb 03, 2012: Aeterna Zentaris Reports Updated Phase I Trial Results For AEZS-108 In Prostate Cancer At ASCO GCS Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Metastatic Hormone Refractory Prostate Cancer, H1 2012
Products under Development for Metastatic Hormone Refractory Prostate Cancer – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Genentech, Inc., H1 2012
Oxford BioMedica plc, H1 2012
Millennium Pharmaceuticals, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Metastatic Hormone Refractory Prostate Cancer Therapeutics – Drug Profile Updates
Metastatic Hormone Refractory Prostate Cancer Therapeutics – Discontinued Products
Metastatic Hormone Refractory Prostate Cancer Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Metastatic Hormone Refractory Prostate Cancer, H1 2012
Products under Development for Metastatic Hormone Refractory Prostate Cancer – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos